What CareDx (CDNA) Said on Its Q3 Earnings Call

CareDx NASDAQ: CDNA reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Naveris.

MarketBeat • 2 hours ago

CareDx Announces Third Quarter 2026 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue of $139 million, an increase of 39% year-over-year Testing Services revenue of $119 million, an increase of 65% year-over-year Testing Services volume of approximately 75,900, an increase of 51% year-ove.

Business Wire • 6 hours ago

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates

CareDx (CDNA) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.28 per share a year ago.

Zacks Investment Research • 2 hours ago

CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus

CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.

Zacks Investment Research • Oct 26, 2026

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado. The findings address several persistent challenges in kidney transplant management: determining the significance of a.

Business Wire • Oct 22, 2026

CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.

Business Wire • Oct 15, 2026

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Sep 25, 2026

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

Benzinga • Sep 23, 2026

5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential

Five stocks stand out for high efficiency, with strong receivables, asset, inventory and operating margin metrics.

Zacks Investment Research • Sep 23, 2026

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

Zacks Investment Research • Sep 14, 2026